Heartflow Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Highlights * Total revenue of $72.9 million, a 57% increase year-over-year * Gross margin of 83.6%, non-GAAP gross margin of 83.8% * Net operating loss of $13.8 million; non-GAAP net operating loss of $5.0 million 2026 Annual Guidance * Total revenue of $262 million to $264 million (approximately 49% to 50% growth year-over-year), compared to previous guidance of $246 million to $250 million (approximately 40% to 42% growth year-over-year) * Non-GAAP gross margin of approximately 82.5%, compared to previous guidance of approximately 82% “Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters,” said John Farquhar, President and CEO of Heartflow. “Our core FFR(CT) business remains durable, our installed base continues to expand rapidly, and activations of Heartflow Plaque Analysis are ramping ahead of plan, with utilization broadening across a wider share of applicable CCTAs. The CCTA market continues to grow rapidly and remains significantly underpenetrated. Strong performance across our diagnostic platform, along with disciplined execution of our commercial, innovation and clinical initiatives, gives us the confidence to raise our 2026 guidance once again. With continued momentum and a scaling business, we believe we are well positioned to extend our market leadership, and we have increased confidence in our path to profitability.”